For the year ending 2025-12-31, NGNE had -$32,741K decrease in cash & cash equivalents over the period. -$78,356K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -90,351 |
| Stock-based compensation expense | 14,183 |
| Depreciation and amortization of property and equipment | 3,043 |
| Asset impairment | 120 |
| Non-cash operating lease expense | 800 |
| Amortization of finance lease right-of-use assets | 49 |
| Amortization and accretion of premiums/discounts on held-to-maturity investments | 4,536 |
| Change in contingent value rights liability | -743 |
| Gain on lease modification | 6 |
| Prepaid expenses and other current assets | -952 |
| Other assets | 58 |
| Accounts payable | 627 |
| Accrued expenses and other liabilities | 1,665 |
| Operating lease liabilities | -2,918 |
| Net cash used in operating activities | -77,173 |
| Purchases of property and equipment | 1,183 |
| Purchases of held-to-maturity investments | 269,513 |
| Proceeds from maturities of held-to-maturity investments | 284,700 |
| Net cash provided by (used in) investing activities | 14,004 |
| Payment of deferred offering costs related to at-the-market sales agreement | 241 |
| Proceeds from sale of common stock in at-the-market sales agreement, net of offering costs | 30,380 |
| Offering costs in connection with pre-closing financing | 0 |
| Transaction costs related to reverse merger | 0 |
| Proceeds from the issuance of common stock upon exercise of options | 266 |
| Proceeds from private financing, net of offering costs paid | 0 |
| Principal payments on finance leases | 61 |
| Proceeds from the issuance of common stock under employee stock purchase plan | 84 |
| Net cash provided by financing activities | 30,428 |
| Net decrease in cash, cash equivalents and restricted cash | -32,741 |
| Cash, cash equivalents and restricted cash at beginning of period | 136,925 |
| Cash, cash equivalents and restricted cash at end of period | 104,184 |
Neurogene Inc. (NGNE)
Neurogene Inc. (NGNE)